Allergan NASH

Double-blind placebo-controlled study to evaluate the efficacy and safety of Cecicriviroc (CVC) for the treatment of Liver Fibrosis in adult subjects with nonalcoholic Steatohepatitis

  • Patients with confirmed liver biopsy of NASH and stage 2 or 3 liver fibrosis
  • CVC acts as an anti-inflammatory and anti-fibrotic agent, that decreases the recruitment and migration of CCR2-expressing monocytes to the site of the liver injury, mainly via CCR2 antagonism, thereby reducing the infiltration of pro-inflammatory, monocyte-derived macrophages into the liver
  • Randomized 2:1 CVC to placebo for 12 months, up to an additional 84 months
  • CVC taken once daily with food
  • Liver biopsy required at screening, month 12 and month 60